Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
O
475830
vs
K
KOSPI 200
Over the past 12 months, Orum Therapeutics Inc has underperformed KOSPI 200, delivering a return of -40% compared to KOSPI 200's +119% growth.
Stocks Performance
475830 vs KOSPI 200
Performance Gap
475830 vs KOSPI 200
Performance By Year
475830 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Orum Therapeutics Inc
Glance View
Orum Therapeutics is a drug development company that works on targeted protein degradation, a way to make harmful disease-causing proteins disappear inside cells. Its main work is to design new medicines in areas like cancer and other hard-to-treat diseases, using biology and chemistry to aim at proteins that traditional drugs often cannot reach. The company does not sell broad consumer products; it builds drug candidates and technology around them. Its customers are mainly pharmaceutical partners and, if its programs succeed, doctors and patients who would use the approved medicines. Orum can make money through research collaborations, licensing deals, milestone payments, and future royalties or product sales if its drug candidates reach the market. In other words, it is a research-driven biotech business that turns scientific platforms into drug programs. What makes Orum different is its focus on protein degradation rather than just blocking a target the usual way. That approach tries to remove the problem protein altogether, which can open the door to treating diseases that are difficult for standard drugs. Its role in the industry is early-stage and highly specialized: it creates drug candidates and may partner with larger drugmakers to move them through development and commercialization.